Targeted Investigational Treatment Analysis of Novel Anti-androgen (TITAN) study : ultralow prostate-specific antigen decline with apalutamide plus androgen-deprivation therapy
Objective: To assess the association between achievement of prostate-specific antigen (PSA) levels ≤0.2 ng/mL (henceforth ‘ultralow’) and clinical outcomes in patients in the ‘Targeted Investigational Treatment Analysis of Novel Anti-androgen’ (TITAN) study (ClinicalTrials.gov Identifier NCT02489318) with metastatic castration-sensitive prostate cancer (mCSPC). Patients and Methods: Patients in th
